Cerivastatin induces type-I fiber-, not type-II fiber-, predominant muscular toxicity in the young male F344 rats

Journal of Toxicological Sciences

Volumn 36, Issue 4, 2011, Pages 445-452

  Obayashi, Hisakuni ^a   Nezu, Yoshikazu ^a   Yokota, Hatsue ^a   Kiyosawa, Naoki ^a   Mori, Kazuhiko ^a   Maeda, Naoyuki ^a   Tani, Yoshiro ^a   Manabe, Sunao ^a   Sanbuissho, Atsushi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Cerivastatin; Extensor digitorum longus; Mitochondria; Myotoxicity; Rat; Soleus

Indexed keywords

CERIVASTATIN; CREATINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CELL VACUOLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME ACTIVITY; EXTENSOR DIGITORUM LONGUS MUSCLE; FISCHER 344 RAT; GAIT; HINDLIMB; HISTOPATHOLOGY; LYSOSOME; MALE; MICROSCOPY; MUSCLE FIBRIL; MUSCLE INJURY; MUSCLE MITOCHONDRION; MUSCLE NECROSIS; MUSCLE WEAKNESS; NONHUMAN; RAT; SARCOPLASMIC RETICULUM; SKELETAL MUSCLE; SKELETAL MUSCLE TOXICITY; SKELETAL MUSCLE TYPE I FIBER; SKELETAL MUSCLE TYPE II FIBER; SOLEUS MUSCLE; STATIN INDUCED MYOTOXICITY; TIBIALIS ANTERIOR MUSCLE; TOXIC MYOPATHY; ULTRASTRUCTURE; WEIGHT REDUCTION;

ANIMALIA; RATTUS;

EID: 79961157905     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.36.445     Document Type: Article

References (23)

1. Amelink, G.J. and Bär, P.R. (1986): Exercise-induced muscle protein leakage in the rat. Effects of hormonal manipulation. J. Neurol. Sci., 76, 61-68.
2. Bergman, M., Salman, H., Djaldetti, M., Alexandrova, S., Punsky, I. and Bessler, H. (2003): Ultrastructure of mouse striated muscle fibers following pravastatin administration. J. Muscle Res. Cell. Motil., 24, 417-420.
3. Biral, D., Ballarin, F., Toscano, I., Salviati, G., Yu, F., Larsson, L. and Betto, R. (1999): Gender and thyroid hormone-related transitions of essential myosin light chain isoform expression in rat soleus muscle during ageing. Acta. Physiol. Scand., 167, 317-323.
4. De Pinieux, G., Chariot, P., Ammi-Saïd, M., Louarn, F., Lejonc, [CDATA]J.L., Astier, A., Jacotot, B. and Gherardi, R. (1996): Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br. J. Clin. Pharmacol., 42, 333-337.
5. Degens, H., Yu, F., Li, X. and Larsson, L. (1998): Effects of age and gender on shortening velocity and myosin isoforms in single rat muscle fibres. Acta. Physiol. Scand., 163, 33-40.
6. Farmer, J.A. (2001): Learning from the cerivastatin experience. Lancet, 358, 1383-1385.
7. Gambelli, S., Dotti, M.T., Malandrini, A., Mondelli, M., Stromillo, M.L., Gaudiano, C. and Federico, A. (2004): Mitochondrial alterations in muscle biopsies of patients on statin therapy. J. Submicrosc. Cytol. Pathol., 36, 85-89.
8. Gauthier, G.F. (1986): Skeletal muscle fiber types. In: Myology: basic and clinical (Engel, A.G. and Banker, B.Q., eds.), pp.255-283
9. McGRAW-HILL BOOK COMPANY, Cleveland, Ohio. Kaufmann, P., Török, M., Zahno, A., Waldhauser, K.M., Brecht, K. and Krähenbühl, S. (2006): Toxicity of statins on rat skeletal muscle mitochondria. Cell. Mol. Life Sci., 63, 2415-2425.
10. Nishimoto, T., Tozawa, R., Amano, Y., Wada, T., Imura, Y. and Sugiyama, Y. (2003): Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes. Biochem. Pharmacol., 66, 2133-2139.
11. Pette, D. and Staron, R.S. (2000): Myosin isoforms, muscle fiber types, and transitions. Microsc. Res. Tech., 50, 500-509.
12. Reijneveld, J.C., Koot, R.W., Bredman, J.J., Joles, J.A. and Bär, P.R. (1996): Differential effects of 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors on the development of myopathy in young rats. Pediatr. Res., 39, 1028-1035.
13. Riggs, J.E., Schochet, S.S.Jr., Kopitnik, T.A. and Gutmann, L. (1986): Target fibers in multiple sclerosis: implications for pathogenesis. Neurology, 36, 297-298.
14. Rosenson, R.S. (2004): Current overview of statin-induced myopathy. Am. J. Med., 116, 408-416.
15. Schaefer, W.H., Lawrence, J.W., Loughlin, A.F., Stoffregen, D.A., Mixson, L.A., Dean, D.C., Raab, C.E., Yu, N.X., Lankas, G.R. and Frederick, C.B. (2004): Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicol. Appl. Pharmacol., 194, 10-23.
16. Seachrist, J.L., Loi, C.M., Evans, M.G., Criswell, K.A. and Rothwell, C.E. (2005): Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity. Toxicol. Sci., 88, 551-561.
17. Sirvent, P., Bordenave, S., Vermaelen, M., Roels, B., Vassort, G., Mercier, J., Raynaud, E. and Lacampagne, A. (2005): Simvastatin induces impairment in skeletal muscle while heart is protected. Biochem. Biophys. Res. Commun., 338, 1426-1434.
18. Smith, P.F., Eydelloth, R.S., Grossman, S.J., Stubbs, R.J., Schwartz, M.S., Germershausen, J.I., Vyas, K.P., Kari, P.H. and MacDonald, J.S. (1991): HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. J. Pharmacol. Exp. Ther., 257, 1225-1235.
19. Staffa, J.A., Chang, J. and Green, L. (2002): Cerivastatin and reports of fatal rhabdomyolysis. N. Engl. J. Med., 346, 539-540.
20. Thompson, P.D., Clarkson, P. and Karas, R.H. (2003): Statin-associated myopathy. JAMA, 289, 1681-1690.
21. Waclawik, A.J., Lindal, S. and Engel, A.G. (1993): Experimental lovastatin myopathy. J. Neuropathol. Exp. Neurol., 52, 542-549.
22. Westwood, F.R., Bigley, A., Randall, K., Marsden, A.M. and Scott, R.C. (2005): Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol. Pathol., 33, 246-257.
23. Westwood, F.R., Scott, R.C., Marsden, A.M., Bigley, A. and Randall, K. (2008): Rosuvastatin: characterization of induced myopathy in the rat. Toxicol. Pathol., 36, 345-352.